Biomea Fusion, Inc. (BMEA)
Biomea Fusion, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Carlos, CA, US. The stock last traded at $1.29, up 1.57% on the session, giving a market capitalisation of $93.3M. On trailing twelve-month figures it carries a trailing P/E of -2.60, a net margin of 0.0%. Its beta of -0.30 implies it has historically moved less than the broad market.
Biomea Fusion, Inc. is a biopharmaceutical firm dedicated to discovering and developing innovative covalent small molecule therapies. These treatments are specifically designed for individuals suffering from genetically defined cancers and various metabolic ailments. The company's primary drug candidate, BMF-219, is a potent and selective covalent inhibitor of menin, engineered for oral administration. Menin plays a crucial role as a transcriptional regulator in the abnormal signaling pathways found across numerous cancer types. Established in 2017, Biomea Fusion's operations are headquartered in Redwood City, California.
Biomea Fusion, Inc. is most often compared with the following Healthcare names: